学术周报 · IF≥10 或专科旗舰刊

胆胰外科领域文献阅读汇编

2026年第47周 (2026-11-20) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
收录论文
16
临床研究
5
基础研究
11
IF≥20
6
IF 10-20
7
子领域
8
期刊种类
9
数据日期
2026-11-20

★本周 Top 10 高影响力文献

#论文期刊IF
1Depletion of Endogenous IL-18 Suppresses Pancreatic Cancer Progression, Reprograms the Tumor Microen...GastroenterologyIF 29.7
2PHGDH Inhibition Confers a Targetable Glutamine Dependency in Pancreatic Cancer.Cancer researchIF 22.6
3Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppr...Cancer researchIF 22.6
4RASA2 Promotes Pancreatic Cancer Metastasis by Activating TGFβ-Dependent Noncanonical Hedgehog Signa...Cancer researchIF 22.6
5Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Prog...Cancer researchIF 22.6
6Cancer-associated fibroblast-derived lactate drives cholangiocarcinoma progression via H4K12la-media...Clinical and molecular hepatologyIF 21.7
7A TROP2-targeting aptamer enables selective drug delivery and potent antitumor activity in pancreati...Science advancesIF 13.9
8Small-Molecule Protein Kinase Inhibitors Approved by the U.S. FDA as Anticancer Agents From 2021 to ...Medicinal research reviewsIF 13.6
9Natural polysaccharides in pancreatic cancer therapy: From immunomodulation and gut microbiota regul...Carbohydrate polymersIF 13.2
10CENPT Promotes Pancreatic Cancer Progression by Activating the RAF/MEK/ERK Signaling Pathway and Tri...Cancer lettersIF 11.8

Ŧ期刊分布统计

期刊篇数IF
Cancer research4IF 22.6
Cancer letters3IF 11.8
Annals of surgery3IF 7.4
Clinical and molecular hepatology1IF 21.7
Medicinal research reviews1IF 13.6
Carbohydrate polymers1IF 13.2
Cancer treatment reviews1IF 10.6
Gastroenterology1IF 29.7
Science advances1IF 13.9

1胰腺癌 (9篇)

基础研究 (9篇)

Cancer letters IF 11.8 2026-11-19 PMID: 43057412
Pancreatic ductal adenocarcinoma (PDAC) is one of the most devastating malignancies, with its incidence and mortality rates remaining particularly discouraging. Elucidating the molecular mechanisms driving PDAC progression and identifying potential therapeutic targets are critical to improve the clinical prognosis of PDAC patients. Accumulating evidence has highlighted the pivotal functions of centromere proteins (CENPs) in tumor progression. Accordingly, this study aimed to screen and identify key CENP family members implicated in PDAC pathogenesis. Through systematic analysis of CENP family proteins in PDAC, we identified CENPT as a critical regulator involved in disease progression. We further validated that CENPT promoted the proliferation and metastasis of PDAC cells via activating the RAF/MEK/ERK signaling pathway through a series of in vitro and in vivo experiments. In addition, CENPT was also found to be implicated in tumor microenvironment remodeling. Single-cell and bulk transcriptomic analyses demonstrated that CENPT expression was positively correlated with Treg cell abundance and an immunosuppressive tumor microenvironment. Further experiments suggested that CENPT upregulated the synthesis and secretion of MIF in PDAC cells, which acted on naive CD4+ T cells to promote the differentiation into Treg cells. This process ultimately induced the formation of an immunosuppressive tumor microenvironment and facilitated PDAC progression, whereas blockade of MIF enhanced the efficacy of immune checkpoint blockade for PDAC. In conclusion, this study revealed the crucial role of CENPT in PDAC progression, and targeting CENPT may serve as one of the potential therapeutic strategies for PDAC.
中文摘要:胰腺导管腺癌(PDAC)是最具破坏性的恶性肿瘤之一,其发病率和死亡率依然令人沮丧。阐明驱动PDAC进展的分子机制并识别潜在的治疗靶点对于改善PDAC患者的临床预后至关重要。越来越多的证据强调了着丝粒蛋白(CENPs)在肿瘤进展中的关键作用。因此,本研究旨在筛选和鉴定参与PDAC发病的关键CENP家族成员。通过对PDAC中CENP家族蛋白的系统分析,我们确定CENPT是参与疾病进展的关键调节因子。我们通过一系列体外和体内实验进一步验证了CENPT通过激活RAF/MEK/ERK信号通路促进PDAC细胞的增殖和转移。此外,还发现CENPT参与肿瘤微环境的重塑。单细胞和批量转录组分析表明,CENPT表达与Treg细胞丰度及免疫抑制性肿瘤微环境呈正相关。进一步实验表明,CENPT上调了PDAC细胞中MIF的合成和分泌,MIF作用于初始CD4+ T细胞促进其分化为Treg细胞。这一过程最终诱导了免疫抑制性肿瘤微环境的形成并促进了PDAC进展,而阻断MIF则增强了免疫检查点阻断疗法对PDAC的疗效。总之,本研究揭示了CENPT在PDAC进展中的关键作用,靶向CENPT可能成为PDAC的一种潜在治疗策略。
Cancer letters IF 11.8 2026-11-19 PMID: 43057411
Pancreatic cancer (PC) commonly develops intrinsic or acquired resistance to gemcitabine (GEM), limiting clinical benefit. To uncover the underlying chromatin and transcriptional programs and identify actionable targets, we integrated ATAC-seq and RNA-seq in a GEM-resistant AsPC-1 subline (AsPC-1 GR) and parental cells. Although global chromatin accessibility decreased in AsPC-1 GR, a set of resistance-specific open regions (Peak_up) emerged. Integrating Peak_up with resistance-upregulated genes (DEG_up) identified 916 candidate resistance-associated genes, and motif analysis further narrowed the regulatory candidates to 23 core transcription factors, with EGR1 prioritized. EGR1 knockdown increased GEM sensitivity and reduced clonogenic growth, whereas EGR1 overexpression promoted survival and tumor growth and weakened GEM efficacy in xenografts. Mechanistically, EGR1 suppressed GEM-induced pyroptosis, with reduced LDH release and decreased IL-1β, consistent with inhibited caspase-1/GSDMD signaling. Multi-evidence integration identified 26 EGR1-linked resistance genes; TCGA survival analysis and validation highlighted SERPINB1 as a key downstream effector. SERPINB1 promoted GEM tolerance by restraining caspase-1 activation, GSDMD cleavage, and cytokine release, indicating inhibition of pyroptosis. Immunoprecipitation-mass spectrometry revealed EGR1 interaction with WDR5, and WDR5/SET1A positively regulated SERPINB1. ChIP-seq data mining and ChIP-qPCR showed co-enrichment of EGR1, WDR5, SET1A, and H3K4me3 at the SERPINB1 promoter, supporting an EGR1-driven epigenetic activation model. Therapeutically, IT25, an inhibitor of EGR1 DNA-binding activity, downregulated SERPINB1, restored GEM-induced caspase-1/GSDMD-mediated pyroptosis, and enhanced the antitumor efficacy of GEM in vivo. Collectively, these findings identify the EGR1-WDR5/SET1A-H3K4me3-SERPINB1 axis as a key driver of GEM resistance in PC and suggest that IT25-based combination therapy may improve GEM efficacy by reactivating pyroptosis.
中文摘要:胰腺癌常对吉西他滨产生固有或获得性耐药,限制了临床疗效。为揭示潜在的染色质与转录调控机制并识别可干预靶点,本研究在吉西他滨耐药的AsPC-1亚系及其亲本细胞中整合了ATAC-seq与RNA-seq数据。尽管AsPC-1 GR整体染色质开放性降低,但仍出现一组耐药特异性开放区域。结合这些区域与耐药上调基因,筛选出916个候选耐药相关基因,并通过基序分析将调控候选者缩小至23个核心转录因子,其中EGR1被优先确定。EGR1敲低增加了吉西他滨敏感性并减少克隆形成能力,而EGR1过表达促进细胞存活与肿瘤生长,并在异种移植模型中削弱吉西他滨疗效。机制上,EGR1抑制吉西他滨诱导的细胞焦亡,表现为LDH释放减少及IL-1β降低,符合caspase-1/GSDMD信号受抑的特征。多证据整合鉴定出26个与EGR1相关的耐药基因;TCGA生存分析及验证结果突出SERPINB1为关键下游效应分子。SERPINB1通过抑制caspase-1活化、GSDMD裂解及细胞因子释放来促进吉西他滨耐受,表明其抑制了细胞焦亡。免疫沉淀-质谱分析显示EGR1与WDR5相互作用,且WDR5/SET1A复合物正向调控SERPINB1。ChIP-seq数据挖掘与ChIP-qPCR结果显示EGR1、WDR5、SET1A及H3K4me3在SERPINB1启动子区共富集,支持EGR1驱动的表观遗传激活模型。治疗方面,EGR1 DNA结合活性抑制剂IT25下调SERPINB1表达,恢复吉西他滨诱导的caspase-1/GSDMD介导的细胞焦亡,并在体内增强吉西他滨抗肿瘤疗效。综上,本研究鉴定出EGR1-WDR5/SET1A-H3K4me3-SERPINB1轴为胰腺癌吉西他滨耐药的关键驱动因素,提示基于IT25的联合疗法可能通过重激活细胞焦亡来改善吉西他滨疗效。
Cancer research IF 22.6 2026-11-19 PMID: 43055344
Pancreatic ductal adenocarcinoma (PDAC) develops in a nutrient-poor microenvironment and progresses from pancreatic intraepithelial neoplasia (PanIN) to invasive carcinoma. Serine metabolism supports tumor growth in many cancers, spurring the development of inhibitors of phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in serine biosynthesis. However, the limited clinical success of PHGDH inhibitors highlights the need to better understand the stage-specific role of de novo serine synthesis during PDAC progression. Here, we showed that PHGDH increases progressively from PanIN to invasive PDAC in human and mouse tissues. In genetically engineered mouse models with inducible PHGDH knockdown, PHGDH loss delayed PDAC development. Acute treatment with the PHGDH inhibitor BI-9593 suppressed de novo serine synthesis, induced cell death, and drove tumor regression. Unexpectedly, PHGDH-deficient tumors did not become more dependent on exogenous serine, and dietary serine/glycine manipulation did not affect tumor development. Instead, stable isotope tracing and metabolomic profiling showed that PHGDH loss reduced ASCT2 expression and impaired glutamine uptake and utilization, creating a metabolic liability that rendered PHGDH-deficient tumors selectively sensitive to the glutamine antagonist DRP-104. Together, these findings reveal a therapeutic vulnerability to combined metabolic targeting in PDAC.
中文摘要:胰腺导管腺癌(PDAC)发生于营养贫乏的微环境中,并从胰腺上皮内瘤变(PanIN)进展为浸润性癌。丝氨酸代谢支持多种癌症的肿瘤生长,推动了作为丝氨酸生物合成限速酶的磷酸甘油酸脱氢酶(PHGDH)抑制剂的开发。然而,PHGDH抑制剂有限的临床成功凸显了更好地理解从头丝氨酸合成在PDAC进展中阶段特异性作用的需求。本研究显示,在人和小鼠组织中,PHGDH从PanIN到浸润性PDAC逐渐增加。在具有可诱导PHGDH敲低的基因工程小鼠模型中,PHGDH缺失延缓了PDAC的发展。急性使用PHGDH抑制剂BI-9593治疗抑制了从头丝氨酸合成,诱导细胞死亡并驱动肿瘤消退。出乎意料的是,PHGDH缺陷的肿瘤并未变得更加依赖外源性丝氨酸,且饮食中的丝氨酸甘氨酸操纵未影响肿瘤发展。相反,稳定同位素示踪和代谢组学谱分析显示,PHGDH缺失降低了ASCT2表达并损害了谷氨酰胺摄取和利用,从而产生一种代谢弱点,使PHGDH缺陷的肿瘤对谷氨酰胺拮抗剂DRP-104选择性敏感。综上所述,这些发现揭示了PDAC中联合代谢靶向的治疗脆弱性。
Cancer research IF 22.6 2026-11-16 PMID: 42696459
Current immunotherapies often fail in immunologically "cold," macrophage-rich tumor microenvironments (TME). Multitargeting approaches that modulate innate-adaptive immune activation represent a promising frontier in cancer immunotherapy. In this study, we developed phagocytic synapse enhancers (PSE), a class of modular immune engagers comprising a high-affinity PD-L1 binder coupled to a macrophage-stimulating peptide, tuftsin. PSEs strengthened effector-target cell interactions and enhanced tumor phagocytosis by bridging tumor PD-L1 to macrophage neuropilin-1, bypassing the classic FcγR-dependent pathways. The PSEs also acted in cis on PD-L1+ macrophages, accelerating the endocytosis and lysosomal compartmentalization of surface PD-L1 and therefore stripping the immunosuppressive checkpoint from the local microenvironment. Beyond physical clearance, the PSEs reprogrammed macrophage phenotype and triggered a robust proinflammatory cytokine and chemokine response. The lead molecule, longPSE, and its half-life-extended variant fused to the albumin-binding domain, ABD-longPSE, showcased superior efficacy than the macrophage enhancer magrolimab in a syngeneic tumor model of colorectal cancer and an orthotopic model of pancreatic cancer. PSE treatment remodeled the TME by inducing phenotypic changes in the lymphoid and myeloid compartments, together with a reduction of tumor-associated macrophages and regulatory T cells. These findings establish PSEs as bifunctional molecules that complement innate and adaptive immune modulation. The bifunctional design offers a versatile approach for next-generation immunotherapies and provides a blueprint for a plug-and-play platform of immune engagers targeting diverse cancer-associated pathways. Bifunctional immune modulators that simultaneously boost phagocytosis and block immune checkpoints offer a versatile strategy to reprogram the tumor microenvironment and advance next-generation cancer immunotherapy.
中文摘要:当前免疫疗法在免疫学「冷」且富含巨噬细胞肿瘤微环境中常告失败。调节先天与适应性免疫激活的多靶点策略是癌症免疫治疗的前沿方向。本研究开发了吞噬突触增强剂,这是一类模块化免疫连接分子,由高亲和力PD-L1结合蛋白与巨噬细胞刺激肽tuftsin组成。该分子通过将肿瘤PD-L1与巨噬细胞神经纤毛蛋白-1桥接,绕过经典FcγR依赖途径,强化效应靶细胞相互作用并增强肿瘤吞噬作用。同时作用于顺式PD-L1阳性巨噬细胞,加速表面PD-L1的内吞及溶酶体区室化,从而清除局部微环境的免疫抑制检查点。除物理清除外,该分子重编程巨噬细胞表型并触发强烈的促炎细胞因子和趋化因子反应。先导分子longPSE及其与白蛋白结合域融合的半衰期延长变体ABD-longPSE在结直肠癌同系肿瘤模型及胰腺癌原位模型中展现出优于巨噬细胞增强剂magrolimab的疗效。治疗通过诱导淋巴和髓系区室表型变化,减少肿瘤相关巨噬细胞和调节性T细胞,重塑肿瘤微环境。这些发现确立该分子为互补先天与适应性免疫调节的双功能分子,其设计为下一代免疫疗法提供通用策略及针对多样化癌症通路的即插即用平台蓝图。
Cancer research IF 22.6 2026-11-16 PMID: 42599212
KRAS mutations are a major driver of pancreatic ductal adenocarcinoma (PDAC). RASA2, a RAS GTPase-activating protein, modulates KRAS protein levels in wild-type (WT) contexts, suggesting that it could play a potential role in PDAC. In this study, we systematically investigated the biological function and molecular mechanisms of RASA2 in PDAC. Integrative analyses of multiple datasets and clinical samples demonstrated that RASA2 was consistently upregulated in KRAS-mutant PDAC and significantly associated with poor prognosis and metastatic progression. Gain- and loss-of-function studies revealed that RASA2 markedly enhanced PDAC cell migration and invasion in both KRAS-mutant and KRAS-WT models, suggesting that its prometastatic activity is largely independent of KRAS mutational status. Transcriptomic and mechanistic analyses revealed that RASA2 activated GLI1 through a TGFβ2-dependent, noncanonical Hedgehog pathway. Mechanistically, RASA2 interacted with RTF1 to promote H2BK120 ubiquitination at the TGFB2 promoter, thereby enhancing TGFB2 transcription and activating downstream GLI1 signaling. Pharmacologic inhibition of TGFβ signaling or genetic silencing of GLI1 effectively suppressed RASA2-driven migratory, invasive, and metastatic phenotypes in vitro and in vivo. Collectively, these findings reveal a mechanism by which RASA2-dependent epigenetic and transcriptional reprogramming promotes metastatic progression and nominate the RASA2-TGFβ2-GLI1 axis as a potential therapeutic target in PDAC. RASA2, preferentially upregulated in KRAS-mutant pancreatic cancer, promotes metastasis through an epigenetically regulated, TGFβ2-induced noncanonical Hedgehog/GLI1 axis, revealing a targetable pathway underlying aggressive tumor progression.
中文摘要:KRAS突变是胰腺导管腺癌的主要驱动因素。RASA2是一种RAS GTP酶激活蛋白,在野生型背景下调节KRAS蛋白水平,提示其在胰腺导管腺癌中可能发挥潜在作用。本研究系统探讨了RASA2在胰腺导管腺癌中的生物学功能和分子机制。对多个数据集和临床样本的综合分析表明,RASA2在KRAS突变的胰腺导管腺癌中持续上调,且与不良预后及转移进展显著相关。功能获得与缺失研究揭示,RASA2在KRAS突变和野生型模型中均显著增强胰腺导管腺癌细胞的迁移和侵袭能力,提示其促转移活性很大程度上独立于KRAS突变状态。转录组学与机制分析显示,RASA2通过TGFβ2依赖的非经典Hedgehog通路激活GLI1。机制上,RASA2与RTF1相互作用,促进TGFB2启动子处的H2BK120泛素化,从而增强TGFB2转录并激活下游GLI1信号。药理学抑制TGFβ信号或基因沉默GLI1可有效抑制体外和体内RASA2驱动的迁移、侵袭及转移表型。综上所述,这些发现揭示了RASA2依赖的表观遗传与转录重编程促进转移进展的机制,并将RASA2-TGFβ2-GLI1轴确定为胰腺导管腺癌的潜在治疗靶点。RASA2在KRAS突变胰腺癌中优先上调,通过表观遗传调控的TGFβ2诱导的非经典Hedgehog/GLI1轴促进转移,揭示了驱动侵袭性肿瘤进展的可靶向通路。
Cancer research IF 22.6 2026-11-16 PMID: 42579812
The Tn antigen, a truncated O-glycan, is frequently elevated in pancreatic ductal adenocarcinoma (PDAC). Multiple therapeutic approaches targeting Tn have been developed, but they have not demonstrated clear efficacy signals in early-phase clinical studies. Improving Tn-targeted strategies in PDAC will require both overcoming the immunosuppressive tumor microenvironment and defining pathways by which truncated O-glycans promote growth and immune evasion. In this study, we show that Tn reshapes the tumor immune landscape of PDAC. Expression of Tn antigen on PDAC cells enhanced proliferation in vitro and tumor growth in vivo. Tn expression remodeled the immune microenvironment, skewing tumor-associated macrophages toward M2-like phenotypes, reducing cross-presenting dendritic cells, and expanding myeloid-derived suppressor cells (MDSC). Single-cell RNA sequencing confirmed the expansion of MDSCs and downregulation of antigen processing and presentation in the immune cell infiltrate of Tn+ tumors. Tumor-intrinsic transcriptomic analyses revealed the activation of TNFα/NF-κB signaling and induction of IL34, a cytokine linked to monocyte survival and differentiation in Tn antigen-expressing tumors. Additionally, high Tn expression in both organoids derived from patients with pancreatic cancer and in PDAC mouse models was associated with increased IL34 expression. The genetic deletion of Il34 in PDAC cells attenuated Tn-driven tumorigenesis and reduced MDSC infiltration, whereas recombinant IL34 promoted myeloid cell differentiation and proliferation in vitro. Together, these findings establish a glyco-immune-cytokine axis in which truncated O-glycans contribute to IL34-mediated immunosuppression, providing mechanistic insights and potential therapeutic targets in PDAC. Altered glycosylation stimulates TNF-α/NF-κB signaling and induces IL-34-mediated accumulation of suppressive myeloid cells in pancreatic cancer, providing a myeloid-mediated mechanism of immunosuppression that could guide the development of therapies targeting glycosylation.
中文摘要:Tn抗原是一种截短的O-聚糖,在胰腺导管腺癌(PDAC)中常显著升高。尽管已开发多种靶向Tn的治疗策略,但在早期临床试验中尚未显示出明确的疗效信号。改进PDAC的Tn靶向策略需克服免疫抑制性肿瘤微环境并明确截短O-聚糖促进生长和免疫逃逸的途径。本研究表明Tn重塑了PDAC的肿瘤免疫景观。在PDAC细胞上表达Tn抗原增强了体外增殖能力和体内肿瘤生长。Tn表达改变了免疫微环境,使肿瘤相关巨噬细胞向M2样表型极化,减少交叉呈递树突状细胞并扩增骨髓源性抑制细胞(MDSC)。单细胞RNA测序证实了Tn阳性肿瘤免疫细胞浸润中MDSC的扩增以及抗原加工和呈递的下调。肿瘤内在转录组分析揭示了TNFα/NF-κB信号通路的激活以及IL34的诱导,后者是一种与表达Tn抗原肿瘤中单核细胞存活和分化相关的细胞因子。此外,在源自胰腺癌患者的类器官和PDAC小鼠模型中,高Tn表达均与IL34表达增加相关。PDAC细胞中Il34的基因敲除减弱了Tn驱动的发瘤作用并减少了MDSC浸润,而重组IL34则在体外促进了髓系细胞的增殖和分化。综上所述,这些发现确立了一种糖-免疫-细胞因子轴,其中截短O-聚糖有助于IL34介导的免疫抑制,为PDAC提供了机制见解和潜在治疗靶点。改变的糖基化刺激TNF-α/NF-κB信号通路并诱导IL-34介导的抑制性髓系细胞积累,提供了一种髓系介导的免疫抑制机制,可指导针对糖基化的疗法开发。
Carbohydrate polymers IF 13.2 2026-11-15 PMID: 42907040
Natural polysaccharides derived from plants, fungi, macroalgae, cyanobacteria, and other marine microorganisms have attracted increasing interest as adjuvant candidates for pancreatic cancer management due to their biocompatibility, structural diversity, and multi-target activities. This review consolidates current knowledge on their anti-pancreatic cancer activities, integrating findings from in vitro, in vivo, and mechanistic studies. We delineate the multi-level regulatory networks through which polysaccharides exert anti-tumor effects via four interconnected mechanisms: direct actions on cancer cells including proliferation inhibition, apoptosis and ferroptosis induction, cell cycle arrest, metastasis suppression, and autophagy modulation; immunomodulation via M1 macrophage polarization, natural killer cell activation, and cytotoxic T lymphocyte mediated killing; restoration of gut microbial homeostasis through beneficial taxa enrichment, intestinal barrier integrity enhancement, short-chain fatty acid elevation, and lipopolysaccharide driven inflammation reduction; and indirect tumor suppression by ameliorating obesity and type 2 diabetes mellitus. The polysaccharide gut microbiota axis emerges as a critical hub integrating these pathways. Structure-activity relationship analysis indicates that low molecular weight, high galacturonic acid content, arabinose and galactose richness, and sulfation may influence activity, although robust attribution requires structurally defined polysaccharides. More than twenty well characterized polysaccharides are documented, with several showing synergistic effects with chemotherapeutics. Despite encouraging preclinical evidence, challenges remain in structural characterization, bioavailability, and clinical validation.
中文摘要:源自植物、真菌、大型海藻、蓝细菌及其他海洋微生物的天然多糖因其生物相容性、结构多样性和多靶点活性,作为胰腺癌管理的辅助候选药物受到越来越多的关注。本综述整合了体外、体内及机制研究中的发现,总结了天然多糖的抗胰腺癌活性。我们描绘了多糖通过四种相互关联的机制发挥抗肿瘤作用的多层次调控网络:包括对癌细胞增殖抑制、凋亡和铁死亡诱导、细胞周期阻滞、转移抑制及自噬调节的直接作用;通过M1巨噬细胞极化、自然杀伤细胞激活及细胞毒性T淋巴细胞介导的杀伤进行免疫调节;通过有益菌群富集、肠道屏障完整性增强、短链脂肪酸升高及脂多糖驱动炎症降低来恢复肠道微生物稳态;以及通过改善肥胖和2型糖尿病间接抑制肿瘤。多糖-肠道微生物轴被视为整合这些通路的关键枢纽。构效关系分析表明,低分子量、高半乳糖醛酸含量、富含阿拉伯糖和半乳糖以及硫酸化可能影响活性,尽管需要结构明确的天然多糖才能进行可靠的归因分析。文献记录了二十多种特征明确的天然多糖,其中几种显示出与化疗药物的协同效应。尽管临床前证据令人鼓舞,但在结构表征、生物利用度和临床验证方面仍面临挑战。
Gastroenterology IF 29.7 2026-11-13 PMID: 43025768
Pancreatic ductal adenocarcinoma (PDAC) exhibits a highly complex tumor microenvironment enriched with both inflammatory and immunosuppressive factors. Interleukin-18 (IL-18), a cytokine of the IL-1 family, is elevated in PDAC and correlates with poor patient outcomes. However, the functional role of IL-18 in PDAC progression and immune regulation remains poorly defined. We generated genetically engineered mouse models with IL-18 depletion in the context of spontaneous PDAC development. Single-cell RNA-sequencing and functional assays were used to analyze PDAC progression, macrophage phenotypes, and cancer cell-macrophage interactions. Mechanistic studies were performed to determine the effects of IL-18 on STAT1 signaling and CD47 expression. The role of IL-18 in therapeutic response was evaluated using KRAS inhibitor (KRASi) treatment models. Elevated IL-18 expression correlated with poor patient survival. Genetic depletion of IL-18 significantly suppressed spontaneous PDAC progression and prolonged survival in mice. Mechanistically, IL-18 promoted cancer cell survival by activating STAT1-dependent CD47 expression, thereby impairing macrophage-mediated phagocytosis of cancer cells. In addition, IL-18 depletion reshaped the tumor immune microenvironment by enriching macrophage populations with enhanced antigen-presenting and phagocytic phenotypes characterized by increased MHCII and CD11c expression. Notably, KRAS inhibitor treatment further increased IL-18 expression in PDAC cells, whereas IL-18 depletion enhanced macrophage-mediated clearance of KRASi-treated cancer cells and improved therapeutic efficacy. IL-18 promotes pancreatic cancer progression by enabling cancer cell survival and immune evasion through macrophage reprogramming. Targeting IL-18 may represent a therapeutic strategy to enhance macrophage-mediated anti-tumor immunity and improve responses to KRAS inhibitor therapies in PDAC.
中文摘要:胰腺导管腺癌(PDAC)具有高度复杂的肿瘤微环境,富含炎症和免疫抑制因子。白细胞介素18(IL-18)属于IL-1细胞因子家族,其在PDAC中表达升高且与患者不良预后相关。然而,IL-18在PDAC进展和免疫调节中的功能作用尚不明确。我们构建了自发PDAC发展背景下IL-18缺失的基因工程小鼠模型。利用单细胞RNA测序和功能实验分析PDAC进展、巨噬细胞表型及癌细胞与巨噬细胞的相互作用。通过机制研究确定IL-18对STAT1信号通路和CD47表达的影响。使用KRAS抑制剂(KRASi)治疗模型评估IL-18在治疗反应中的作用。IL-18高表达与患者生存期缩短相关。IL-18基因缺失显著抑制小鼠自发PDAC进展并延长其生存期。机制上,IL-18通过激活STAT1依赖性CD47表达促进癌细胞存活,从而损害巨噬细胞介导的癌细胞吞噬作用。此外,IL-18缺失通过富集具有增强抗原呈递和吞噬表型的巨噬细胞群重塑肿瘤免疫微环境,其特征为MHCII和CD11c表达增加。值得注意的是,KRAS抑制剂治疗进一步增加了PDAC细胞中IL-18的表达,而IL-18缺失增强了巨噬细胞介导的清除经KRASi处理的癌细胞的能力并提高了治疗效果。IL-18通过促进癌细胞存活和免疫逃逸(经由巨噬细胞重编程)促进胰腺癌进展。靶向IL-18可能代表一种增强巨噬细胞介导的抗肿瘤免疫并改善PDAC对KRAS抑制剂治疗反应的策略。
Science advances IF 13.9 2026-11-13 PMID: 43013672
Pancreatic ductal adenocarcinoma (PDAC) remains difficult to treat, highlighting the need for strategies that selectively deliver cytotoxic agents to tumor cells. Trophoblast cell-surface antigen 2 (TROP2) has been proposed as a candidate therapeutic target in PDAC, but non-antibody-based delivery formats remain underexplored. Using protein-SELEX, we identified T17, a high-affinity aptamer that specifically binds to TROP2, and conjugated it to monomethyl auristatin E through an MC-Val-Cit-PAB linker to generate the aptamer-drug conjugate T17-M. Preclinical evaluation in cellular and animal models showed that T17-M retained TROP2-dependent binding, underwent clathrin-mediated internalization and lysosomal processing, and suppressed tumor growth in cell-line-derived and patient-derived xenografts. T17-M also reduced liver metastasis and induced calreticulin exposure, ATP release, and HMGB1 secretion, consistent with immunogenic cell death. In immunocompetent models, T17-M promoted dendritic-cell activation and CD8+ T cell infiltration, while its combination with PD-1 blockade further enhanced tumor control and prolonged survival. These findings provide preclinical proof-of-concept for T17-M as an alternative TROP2-targeted drug-delivery strategy for PDAC.
中文摘要:胰腺导管腺癌治疗困难,亟需能将细胞毒性药物选择性递送至肿瘤细胞的策略。滋养层细胞表面抗原2被提议作为胰腺导管腺癌的潜在治疗靶点,但基于非抗体形式的递送系统研究尚不充分。本研究通过蛋白质SELEX技术筛选出高亲和力且特异性结合TROP2的适配体T17,并通过MC-Val-Cit-PAB连接臂将其与单甲基澳瑞他汀E偶联,生成适配体药物偶联物T17-M。在细胞和动物模型中的临床前评估显示,T17-M保留了依赖TROP2的结合能力,经历网格蛋白介导的内吞作用和溶酶体加工,并在细胞系来源及患者来源异种移植模型中抑制肿瘤生长。T17-M还能减少肝转移并诱导钙网蛋白暴露、ATP释放和HMGB1分泌,符合免疫原性细胞死亡特征。在免疫健全模型中,T17-M促进树突状细胞活化和CD8+ T细胞浸润,其与PD-1阻断联合使用进一步增强了肿瘤控制效果并延长了生存期。这些发现为T17-M作为胰腺导管腺癌的替代性TROP2靶向药物递送策略提供了临床前概念验证。

2肝胆癌 (1篇)

临床研究 (1篇)

Cancer letters IF 11.8 2026-11-18 PMID: 43051478
Hepatobiliary cancers include hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC). We aimed to assess incidence, mortality, survival, and premature mortality of hepatobiliary cancers by subtype in China and progress toward Sustainable Development Goal (SDG) target 3.4. We conducted a nationwide population-based study using data on hepatobiliary cancer cases from 919 cancer registries in China, covering 44.9% of the national population. We estimated incidence, mortality, and premature mortality for 2024 using subtype distributions of HCC, ICC, ECC, and GBC. We quantified 2010-2019 trends using average annual percent changes (AAPCs). Age-standardized 5-year relative survival was estimated using data from 281 registries. Linear trend projections were applied to assess whether current trajectories are sufficient to meet SDG target. In 2024, an estimated 387,600 hepatobiliary cancer cases and 329,500 deaths occurred in China. Age-standardized incidence, mortality, and premature mortality declined, whereas overall 5-year relative survival remained stable at 14.8%. HCC showed sustained declines in incidence, mortality, and premature mortality. ICC incidence increased by 2.4% annually, while ECC mortality and premature mortality rose by 1.6% and 2.8% per year, respectively. HCC was the only subtype with improved survival and was projected to meet the SDG 3.4 premature mortality target by 2030. The disease burden of hepatobiliary cancers remains high in China. Rising ICC and ECC burdens underscore the need to shift from a predominantly HCC-focused approach toward subtype-specific, risk-targeted interventions.
中文摘要:肝胆癌包括肝细胞癌(HCC)、肝内胆管癌(ICC)、肝外胆管癌(ECC)和胆囊癌(GBC)。本研究旨在评估中国不同亚型肝胆癌的发病率、死亡率、生存率及过早死亡率,并分析其向可持续发展目标(SDG)3.4指标迈进的进展。我们利用中国919个癌症登记处提供的肝胆癌病例数据开展了一项全国性人群研究,覆盖全国44.9%的人口。我们基于HCC、ICC、ECC和GBC的亚型分布估算了2024年的发病率、死亡率和过早死亡率。通过平均年度百分比变化(AAPC)量化了2010至2019年的趋势。利用281个登记处的数据估算了年龄标准化5年相对生存率。采用线性趋势预测评估当前轨迹是否足以实现SDG目标。2024年中国估计有387,600例肝胆癌病例和329,500例死亡。年龄标准化的发病率、死亡率和过早死亡率均呈下降趋势,而总体5年相对生存率稳定在14.8%。HCC的发病率、死亡率和过早死亡率持续下降。ICC发病率每年增加2.4%,而ECC死亡率和过早死亡率分别每年上升1.6%和2.8%。HCC是唯一生存率改善的亚型,预计将在2030年达到SDG 3.4过早死亡率目标。中国肝胆癌的疾病负担仍然很高。ICC和ECC负担的上升凸显了从以HCC为主的策略转向针对特定亚型和风险目标的干预措施的必要性。

3胆管癌/胆道手术 (1篇)

基础研究 (1篇)

Clinical and molecular hepatology IF 21.7 2026-11-17 PMID: 43041058
Cholangiocarcinoma (CCA) is a highly aggressive malignancy, and chemoresistance is a major cause of poor prognosis. This study aimed to elucidate the molecular mechanisms driving CCA progression from a tumor microenvironment perspective and to develop novel strategies to enhance chemosensitivity. Single-cell RNA-seq, untargeted metabolomics, and proteomics were used to identify the source of lactate in the CCA microenvironment and the metabolic reprogramming of cancer-associated fibroblasts (CAFs). To evaluate the impact of CAF-derived lactate on prognosis, we performed AAV-mediated MCT4 knockdown followed by hydrodynamic injection to induce a CCA model. Co-culture models were combined with genome-wide CUT&Tag, MeRIP-seq, and RIP-seq to resolve epigenetic and post-transcriptional regulatory mechanisms. The antitumor effects of 7ACC1 (a small molecule reported to inhibit lactate uptake), alone or in combination with gemcitabine, were assessed in subcutaneous and orthotopic liver xenograft models. CAFs undergo glycolytic reprogramming, resulting in aberrant lactate accumulation. Mechanistically, CAF-derived lactate induces H4K12 lactylation (H4K12la) in CCA cells, which in turn activates the IGF2BP3/ATF3 axis to upregulate oxidative phosphorylation and promote tumor progression. The lactate shuttle inhibitor 7ACC1, combined with gemcitabine, exerts promising antitumor effects. Clinically, high levels of MCT4, α SMA, and H4K12la are associated with poor prognosis in patients with CCA. These findings reveal that CAFs drive CCA progression via lactate-induced H4K12la, which activates the IGF2BP3/ATF3 axis. The findings provide a preclinical rationale for further evaluation of lactate-uptake-targeting strategies in combination with gemcitabine for CCA.
中文摘要:胆管癌是一种高度侵袭性恶性肿瘤,化疗耐药是导致预后不良的主要原因。本研究旨在从肿瘤微环境角度阐明驱动胆管癌进展的分子机制,并开发增强化疗敏感性的新策略。利用单细胞RNA测序、非靶向代谢组学和蛋白质组学技术,鉴定了胆管癌微环境中乳酸的来源以及癌症相关成纤维细胞的代谢重编程情况。为评估癌症相关成纤维细胞来源乳酸对预后的影响,我们采用AAV介导的MCT4敲低结合水动力注射诱导构建了胆管癌模型。结合共培养模型与全基因组CUT&Tag、MeRIP-seq及RIP-seq技术,解析了表观遗传和转录后调控机制。在皮下和原位肝异种移植模型中评估了7ACC1(一种被报道可抑制乳酸摄取的小分子)单独或与吉西他滨联合使用的抗肿瘤效果。癌症相关成纤维细胞发生糖酵解重编程,导致乳酸异常积聚。机制上,癌症相关成纤维细胞来源的乳酸诱导胆管癌细胞中的H4K12乳酸化修饰,进而激活IGF2BP3/ATF3轴以上调氧化磷酸化并促进肿瘤进展。乳酸穿梭抑制剂7ACC1联合吉西他滨展现出良好的抗肿瘤效果。临床数据显示,MCT4、αSMA和H4K12la的高表达与胆管癌患者的不良预后相关。这些发现揭示癌症相关成纤维细胞通过乳酸诱导的H4K12la驱动胆管癌进展,该修饰激活了IGF2BP3/ATF3轴。研究结果为进一步评估靶向乳酸摄取策略联合吉西他滨治疗胆管癌提供了临床前依据。

4胰腺囊肿/IPMN (1篇)

临床研究 (1篇)

Annals of surgery IF 7.4 2026-11-17 PMID: 43040604
To evaluate the natural history, especially concomitant pancreatic ductal adenocarcinoma (cPDAC) risk in patients with branch-duct intraductal papillary mucinous neoplasm (BD-IPMN) without worrisome features (WF) or high-risk stigmata (HRS). BD-IPMNs without WF/HRS are considered low-risk, yet optimal surveillance strategies remain uncertain. In a prospective multicenter Japan Pancreas Society registry, 1234 patients with BD-IPMN without WF/HRS underwent imaging and laboratory surveillance every 6 months for up to 5.17 years. Cumulative incidence, standardized incidence ratios (SIRs), and competing-risk analyses were performed to assess advanced pancreatic neoplasia, defined as IPMN high-grade dysplasia (IPMN-HGD), invasive IPMN, or cPDAC, and associated risk factors. Outcomes were also evaluated under simulated guideline-recommended extended surveillance intervals. During 5.17 years of follow-up, advanced pancreatic neoplasia developed in 26 patients: 10 IPMN-HGD/invasive IPMN and 16 cPDAC. The 5.17-year cumulative incidence was 2.48%; SIRs relative to the general population were 8.01 overall, 3.07 for IPMN-HGD/invasive IPMN, and 4.91 for cPDAC. The cPDAC SIRs were 6.21 and 3.02 for cysts <20 mm and ≥20 mm, respectively. Diabetes history and mural nodule development predicted IPMN-HGD/invasive IPMN, whereas CA19-9 elevation and new or worsening diabetes predicted cPDAC. Of 19 patients eligible for surveillance interval extension, 13 (68%) had a later simulated detection date. Patients with BD-IPMN without WF/HRS at baseline had 3.07 and 4.91 times the incidences of IPMN-HGD/invasive IPMN and cPDAC expected in the general population, respectively. Surveillance based solely on cyst stability may warrant caution regarding the timely detection of surgically resectable pancreatic cancer.
中文摘要:旨在评估无警示特征或高危征象的分支型导管内乳头状黏液性肿瘤患者的自然史,特别是合并性胰腺导管腺癌的风险。尽管此类病变被视为低风险,但最佳监测策略仍不明确。在一项日本胰腺学会的前瞻性多中心登记研究中,1234名无警示特征或高危征象的分支型导管内乳头状黏液性肿瘤患者接受了长达5.17年的每6个月一次的影像学和实验室监测。通过计算累积发病率、标准化发病率比及竞争风险分析,评估了定义为高级别上皮内瘤变、浸润性或合并性胰腺导管腺癌等晚期胰腺新生物的发生情况及相关风险因素,并模拟了指南推荐的延长监测间隔下的结局。在5.17年的随访中,26名患者出现晚期胰腺新生物,其中10例为高级别上皮内瘤变或浸润性病变,16例为合并性胰腺导管腺癌。5.17年累积发病率为2.48%;与普通人群相比,总体标准化发病率比为8.01,高级别上皮内瘤变或浸润性病变为3.07,合并性胰腺导管腺癌为4.91。囊肿小于20毫米和大于等于20毫米的合并性胰腺导管腺癌标准化发病率比分别为6.21和3.02。糖尿病病史和壁结节出现预测高级别上皮内瘤变或浸润性病变,而CA19-9升高及新发或恶化糖尿病预测合并性胰腺导管腺癌。在19名符合延长监测间隔条件的患者中,13名(68%)的模拟检出日期延后。基线时无警示特征或高危征象的分支型导管内乳头状黏液性肿瘤患者,其高级别上皮内瘤变或浸润性病变及合并性胰腺导管腺癌的发病率分别为普通人群的3.07倍和4.91倍。仅基于囊肿稳定性的监测在及时检测可手术切除的胰腺癌方面可能需谨慎对待。

5胆囊切除 (1篇)

临床研究 (1篇)

Annals of surgery IF 7.4 2026-11-16 PMID: 43037576
Evaluate operative complexity, clinical outcomes, and drivers of health care utilization after aborted minimally invasive cholecystectomy (MIC). Although MIC is a standard approach, minimally invasive techniques cannot always be completed safely. Operative complexity, patient characteristics, and clinical outcomes after aborted MIC remain poorly defined. We conducted a retrospective review of patients referred to our tertiary medical center between 2015 and 2025 after aborted MIC. All patients subsequently underwent definitive open cholecystectomy. Multivariable regression models were used to identify predictors of hospital length of stay (LOS), postoperative complications, and 30-day readmission. The cohort included 176 patients. The most common reasons for aborting MIC were fibrotic, contracted, and intrahepatic gallbladder (38.6%), dense adhesions (23.3%), inability to safely separate the gallbladder from adjacent organs (22.7%), and unsafe anatomy (19.3%). Complex biliary pathology was confirmed intraoperatively in 30.6% of patients; concomitant procedures were required in 43.4%, and the overall complication rate was 18.7%, including a bile leak rate of 5.1%. No bile duct injury was observed. Median LOS was 2 days, the readmission rate was 6.3%, and mortality was 0.5%. Higher comorbidity burden, greater blood loss, and performance of concomitant procedures independently predicted longer LOS. No variables were independently associated with complications or readmission. Aborted MIC often reflects unrecognized complex biliary pathology rather than technical failure. A definitive open surgical approach with biliary reconstructive capability achieves acceptable short-term outcomes. Early conversion or referral should be considered a proactive safety strategy, with important implications for surgical training, decision-making, and system-level escalation and referral pathways.
中文摘要:评估 aborted 微创胆囊切除术后的手术复杂性、临床结局及医疗资源利用驱动因素。尽管微创技术是标准术式,但有时无法安全完成。本研究对2015年至2025年间因 aborted 微创胆囊转诊至三级医疗中心的患者进行了回顾性分析,所有患者随后均接受了确定性开腹胆囊切除术。采用多变量回归模型识别住院时间、术后并发症及30天再入院率的预测因素。队列共纳入176例患者。中止微创手术的最常见原因包括纤维化、挛缩及肝内胆囊(38.6%)、致密粘连(23.3%)、无法安全将胆囊与邻近器官分离(22.7%)以及解剖结构不安全(19.3%)。术中证实存在复杂胆道病理的比例为30.6%,需联合手术者占43.4%,总体并发症发生率为18.7%,其中胆汁漏发生率为5.1%。未观察到胆管损伤。中位住院时间为2天,再入院率为6.3%,死亡率为0.5%。合并症负担较重、出血量较多及行联合手术独立预测更长的住院时间。无变量与并发症或再入院率独立相关。Aborted 微创胆囊切除术往往反映未被识别的复杂胆道病理而非技术失败。具备胆道重建能力的确定性开腹手术可获得可接受的短期结局。早期转换术式或转诊应被视为主动的安全策略,对外科培训、决策制定及系统层面的升级与转诊路径具有重要启示。

6胆道肿瘤 (1篇)

基础研究 (1篇)

Medicinal research reviews IF 13.6 2026-11-16 PMID: 43036254
Protein kinases coordinate cellular proliferation, differentiation, survival, metabolism, and stress responses, and dysregulated kinase signalingf is a defining feature of many malignancies. From 2021 through 2025, the U.S. Food and Drug Administration (U.S. FDA) approved 26 small-molecule kinase inhibitors for cancer therapy, extending precision treatment across non-small-cell lung cancer, hematologic malignancies, breast and ovarian cancers, cholangiocarcinoma, renal cell carcinoma, glioma, and other kinase-driven tumors. The approved agents illustrate advances in medicinal chemistry and translational pharmacology that include covalent inhibitors such as sotorasib and futibatinib, mutation-selective inhibitors such as taletrectinib and zongertinib, allosteric inhibitors such as asciminib and mirdametinib, and multitarget or combination strategies such as avutometinib plus defactinib. Improvements in central nervous system exposure, mutant selectivity, dosing durability, and biomarker-defined patient selection have broadened clinical utility. This Review integrates the discovery background, mechanism of action, synthetic route, pharmacological properties, clinical efficacy, safety, and regulatory context of these agents. It also evaluates acquired resistance, target-related and off-target toxicities, heterogeneous evidence supporting accelerated approvals, and the uncertain translation of biochemical potency into durable survival benefit. Successful kinase drug development therefore requires molecular design to be aligned with clinically achievable exposure, validated biomarkers, resistance surveillance, and confirmatory evidence.
中文摘要:蛋白激酶协调细胞增殖、分化、存活、代谢及应激反应,激酶信号失调是许多恶性肿瘤的特征性表现。2021年至2025年间,美国食品药品监督管理局批准了26种小分子激酶抑制剂用于癌症治疗,将精准治疗扩展至非小细胞肺癌、血液系统恶性肿瘤、乳腺癌和卵巢癌、胆管癌、肾细胞癌、胶质瘤及其他由激酶驱动的肿瘤。获批药物体现了药物化学和转化药理学方面的进展,包括索托拉西布和伏比替尼等共价抑制剂,塔雷曲替尼和宗替尼等突变选择性抑制剂,阿司米尼布和米尔达美替尼等变构抑制剂,以及阿武替尼联合德法替尼等多靶点或联合策略。中枢神经系统渗透性、突变选择性、给药持久性及生物标志物定义的患者选择方面的改进扩大了其临床效用。本综述整合了这些药物的发现背景、作用机制、合成路线、药理学特性、临床疗效、安全性及监管背景。同时评估了获得性耐药、靶点相关及脱靶毒性、支持加速审批的证据异质性,以及生化效力转化为持久生存益处的不确定性。因此,成功的激酶药物开发要求分子设计与临床可实现的暴露量、验证的生物标志物、耐药监测及确认性证据相一致。

7胆管癌 (1篇)

临床研究 (1篇)

Cancer treatment reviews IF 10.6 2026-11-13 PMID: 43044180
The role of neoadjuvant systemic therapy in resectable biliary tract cancer (BTC) remains uncertain. We conducted a systematic review and meta-analysis to assess the feasibility, surgical outcomes, radiological activity, and survival associated with neoadjuvant treatment. PubMed/MEDLINE, Embase, and CENTRAL were searched through April 30, 2026 for prospective phase II-III trials evaluating neoadjuvant systemic therapy followed by surgery in resectable BTC. Binary outcomes were pooled using random-effects models. Individual patient data were reconstructed from published Kaplan-Meier curves, and landmark survival estimates were synthesized using random-effects meta-analysis. Six prospective trials comprising seven active neoadjuvant treatment arms were included. Pooled neoadjuvant-to-surgery completion and curative-intent resection rates were 79.0% (95% CI, 63.0-89.0) and 71.0% (95% CI, 54.0-84.0), respectively. The pooled objective response rate was 21.2% (95% CI, 9.0-42.3), and the intention-to-treat R0 resection rate was 63.6% (95% CI, 44.7-79.0). Pooled overall survival was 84.0% (95% CI, 78.0-89.0), 63.0% (55.0-71.0), and 51.0% (44.0-59.0) at 12, 24, and 36 months, respectively. Corresponding recurrence-related survival estimates were 60.0% (51.0-69.0), 41.0% (33.0-50.0), and 37.0% (30.0-45.0). Findings were consistent across sensitivity analyses. Neoadjuvant systemic therapy is feasible in selected patients with resectable BTC, although a substantial proportion do not ultimately undergo curative surgery. Emerging prospective evidence supports further evaluation of perioperative strategies, particularly in high-risk disease, but randomized trials against contemporary surgery-first approaches are required before routine adoption.
中文摘要:可切除胆道癌(BTC)的新辅助全身治疗作用尚不明确。我们进行了系统评价和荟萃分析,以评估新辅助治疗的可行性、手术结局、放射学活性和生存情况。检索了截至2026年4月30日PubMed/MEDLINE、Embase和CENTRAL数据库中评估可切除BTC患者接受新辅助全身治疗后手术的 prospective phase II-III 试验。采用随机效应模型汇总二分类结局。从已发表的Kaplan-Meier曲线重建个体患者数据,并使用随机效应荟萃分析综合地标生存估计值。纳入了六项前瞻性试验,包含七个活跃的新辅助治疗组。新辅助治疗至手术完成率 pooled 为79.0%(95% CI, 63.0-89.0),根治性切除率 pooled 为71.0%(95% CI, 54.0-84.0)。客观缓解率 pooled 为21.2%(95% CI, 9.0-42.3),意向治疗R0切除率为63.6%(95% CI, 44.7-79.0)。总生存率在12、24和36个月时的 pooled 估计值分别为84.0%(95% CI, 78.0-89.0)、63.0%(95% CI, 55.0-71.0)和51.0%(95% CI, 44.0-59.0)。相应的复发相关生存估计值分别为60.0%(95% CI, 51.0-69.0)、41.0%(95% CI, 33.0-50.0)和37.0%(95% CI, 30.0-45.0)。敏感性分析结果一致。新辅助全身治疗在选定的可切除BTC患者中是可行的,尽管相当一部分患者最终未接受根治性手术。新兴的前瞻性证据支持进一步评估围手术期策略,特别是在高危疾病中,但在常规采用之前需要与当代先手术方案进行随机对照试验。

8肝转移瘤切除 (1篇)

临床研究 (1篇)

Annals of surgery IF 7.4 2026-11-13 PMID: 43021470
To evaluate whether integrated primary tumor biology, combining primary tumor location and RAS/BRAF status, defines recurrence phenotypes and survival trajectories after liver resection for colorectal liver metastases (CRLM). Selection for resection remains largely morphology-based, although tumor biology strongly influences post-hepatectomy outcomes. Primary tumor site and RAS/BRAF status are individually prognostic, but whether their integration identifies distinct post-resection trajectories is unclear. An international multicenter cohort of patients undergoing liver resection for CRLM between 2017 and 2023 was analyzed. Integrated biology was defined a priori as left-sided-wild-type, right-sided-wild-type, rectal-wild-type, left-sided-RAS-mutant, right-sided-RAS-mutant, rectal RAS-mutant, and BRAF-mutant disease. Primary outcomes were recurrence-free survival (RFS) and overall survival (OS). Secondary outcomes included early recurrence, disseminated first recurrence, and first recurrence phenotype. Among 3162 patients from 44 centers, 2415 (76.4%) developed recurrence and 1342 (42.4%) died. Integrated biology was independently associated with both RFS and OS (global P <0.001 for both). Compared with left-WT tumors, the highest mortality risks were observed in BRAF-mutant disease [hazard ratio (HR): 2.68, 95% CI: 2.02-3.57, P <0.001] and right-RAS-mutant disease (HR: 2.32, 95% CI: 1.94-2.79, P <0.001). Integrated biology was also associated with early recurrence, disseminated first recurrence, and first recurrence phenotype. Rectal-RAS-mutant tumors had the strongest association with lung-only recurrence [relative risk ratio (RRR): 3.38, 95% CI: 2.22-5.13, P <0.001] and disseminated recurrence (RRR: 2.57, 95% CI: 1.86-3.55, P <0.001) relative to liver-only recurrence. Integrated primary tumor biology identifies clinically distinct post-hepatectomy disease trajectories after CRLM resection. Combining primary tumor site with RAS/BRAF status may support preoperative counseling, surveillance planning, and trial stratification.
中文摘要:本研究旨在评估整合的原发肿瘤生物学特征(结合原发肿瘤部位与RAS/BRAF状态)是否能在结直肠癌肝转移(CRLM)肝切除术后定义复发表型及生存轨迹。尽管目前手术选择主要基于形态学,但肿瘤生物学对肝切除后的预后具有强烈影响。虽然原发肿瘤部位和RAS/BRAF状态各自具有预后价值,但其整合是否能识别出不同的术后轨迹尚不明确。本研究分析了2017年至2023年间接受CRLM肝切除术患者的国际多中心队列数据。预先定义的整合生物学特征包括左侧野生型、右侧野生型、直肠野生型、左侧RAS突变型、右侧RAS突变型、直肠RAS突变型及BRAF突变型疾病。主要终点为无复发生存期(RFS)和总生存期(OS)。次要终点包括早期复发、首次复发的弥漫性特征及首次复发表型。在来自44个中心的3162名患者中,2415人(76.4%)出现复发,1342人(42.4%)死亡。整合生物学特征与RFS和OS均独立相关(两者全局P值均小于0.001)。与左侧野生型肿瘤相比,BRAF突变型疾病[风险比(HR):2.68,95%置信区间(CI):2.02-3.57,P < 0.001]和右侧RAS突变型疾病(HR:2.32,95% CI:1.94-2.79,P < 0.001)观察到最高的死亡风险。整合生物学特征还与早期复发、首次复发的弥漫性特征及首次复发表型相关。与仅肝内复发相比,直肠RAS突变型肿瘤与仅肺转移复发[相对风险比(RRR):3.38,95% CI:2.22-5.13,P < 0.001]和弥漫性复发(RRR:2.57,95% CI:1.86-3.55,P < 0.001)具有最强的相关性。整合的原发肿瘤生物学特征可识别CRLM切除术后临床上 distinct 的肝切除后疾病轨迹。将原发肿瘤部位与RAS/BRAF状态相结合,可能有助于术前咨询、监测计划制定及试验分层。